

Domperidone suspension 1 mg/mL (100 mL)

Patient's name			Storage condi	tion	In	a refrigerator		At room	temnerature	
	-			Storage condition		in a reingerator			At room temperature	
NHI			Temperature		2-8°C			≤ 25°C		
Date compounded			Shelf life		30 days			30 days		
Batch number			Recommended storage		See note below		,	V		
Ingredients required a	ind formula:									
Ingredient	Supplier	Batch number	Expiry date	Standa formu		Quantity dispensed	Dis by	pensed	Checked by	
Domperidone 10 mg tablets				10 ta	blets					
Ora-Blend [®]	Perrigo			to 10	0 mL					
OR		-	1	r			1			
Ora-Plus [®]	Perrigo			5	0 mL					
Ora-Sweet [®]	Perrigo			5	0 mL					
Ora-Blend SF [®] or Ora-	Sweet SF [®] (sug	ar free) can b	be substituted	? Ye	S					
Calculations performed by										
Calculations checked by (pharmacist)										
Area cleared for proce										
Instructions to compo	und suspensio	n:								
1. If Ora-Blend®	unavailable: F	Pre-mix the O	ra-Plus [®] and C	Dra-Swe	et® to	form the dilu	uent.			
2. Crush tablets i	in mortar to a f	ine powder.								
3. Add diluent (C	Dra-Blend [®] or p	orepared dilue	ent) to form a	smooth	n paste	2.				
4. Gradually add	the diluent an	d transfer to	the final meas	uring fl	ask, ri	nsing the mo	rtar v	well. Mix	well.	
5. Make up to th	e final volume	and mix well								
6. Label and pacl	kage product a	ppropriately.								
Labels										
Attach product label and auxiliary labels:							Label checked by			

Page 1 of 2



Domperidone suspension 1 mg/mL (100 mL)

Final yield		mL		Checked by						
Final appearance of product		Pale white to pink suspension.								
Container		Amber plastic mission bottle.								
Compounded by		Name:	Sigi	nature:	Date:					
Final check and product release		Name:	Sigi	nature:	Date:					
 Special instructions: Shake well before use. Store at room temperature. Solubility is only 50 microgram/mL so the domperidone will be in suspension. Storage at room temperature is preferred as if stored in a refrigerator the preparation will be more viscous and harder to re-suspend. 										
 References: 1. Allen LV, Jr. Int J Pharm Compd, 2006. 2. Ensom MH, Decarie D, Hamilton D. J Inform Pharmacother, 2002; 8: 100-104. 										
Prepared by	repared by New Zealand Compounding Working Group									
Approved by	Medication Safety Expert Advisory Group of Health Quality and Safety Commission NZ									
Hosted by		ical Society of New Zealand rmulations in the Practice Support section of the PSNZ website								
Version number	2.0		Version approval date		16/10/18					
Document review due	01/11/20									

Disclaimer: this batch sheet has been designed to provide guidance and standardised formulations for New Zealand pharmacists. Please read and familiarise yourself with the general guidance for compounding oral liquids (available on the PSNZ web site) before use. Information was considered accurate at the time of publication.